Clinical Trial Detail

NCT ID NCT04089553
Title An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors AstraZeneca
Indications

prostate cancer

Therapies

AZD4635 + Durvalumab

AZD4635 + Oleclumab

Age Groups: adult senior

No variant requirements are available.